Evidence map›Paper›PMID 33389826›Full record

ArticleVeterinary medicine and science2021

Clinical efficacy of intravaginal recombinant lysostaphin administration on endometritis in sows.

Guizi Ye, Jinjiang Huang, Guodong Li, Jien Zhang, Yongxue Sun, Dongping Zeng, Wenbin Bao, Jiang Zhong, Qingshan Huang

Abstract read
In one paragraph

Article in Veterinary medicine and science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Aqueous Extract ofVeterinary sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Active components and molecular mechanism ofFrontiers in veterinary science · 2022
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guizi YeState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, P.R.China.ORCID 0000-0003-1576-0128
Jinjiang HuangKunshan Bio-Green Biotechnology Co., Ltd, Kunshan, P.R.China.
Guodong LiShanghai High-Tech United Bio-Technological R&D Co., Ltd, Shanghai, China.
Jien ZhangShanghai High-Tech United Bio-Technological R&D Co., Ltd, Shanghai, China.
Yongxue SunLaboratory of Veterinary Pharmacology South, China Agricultural University, Guangzhou, P.R.China.
Dongping ZengLaboratory of Veterinary Pharmacology South, China Agricultural University, Guangzhou, P.R.China.
Wenbin BaoYangzhou University, Yangzhou, P.R.China.
Jiang ZhongState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, P.R.China.
Qingshan HuangState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, P.R.China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant lysostaphin has been used for the treatment of cow endometritis and mastitis in China. To our knowledge, no scientific effort has been made to evaluate the efficacy of lysostaphin in sows with clinical endometritis. Lysostaphin, loaded in effervescent tablets that were completely foamed and dissolved within 30 min in the presence of water or body fluids and released active lysostaphin, were administered vaginally on endometritis sows in this study. The clinical recovery, bacterial clearance and reproductive performance of sows with endometritis were investigated. We found that the 400U dosage (400U lysostaphin/pill/time, repeat once on the third day, a total of two times, with 10% oxytetracycline uterine injection as a control) is the most effective treatment. Staphylococcus aureus was the most prevalent finding (34%, n = 188), followed by Streptococcus (32%, n = 181), Escherichia coli (19%, n = 104) and other bacilli (15%, n = 83) before treatment by drugs. Administration of lysostaphin resulted in an extremely significant (p < .01) reduction in S. aureus (0.18 ± 0.25 from 4.57 ± 0.33) and Streptococcus (0.11 ± 0.14 from 3.88 ± 0.29), as well as a significant (p < .05) reduction in E. coli (0.55 ± 0.42 from 3.11 ± 0.14). Mixed infections (83%) were predominant before treatment, in contrast to single infections (61%) after treatment. Large-scale trials were conducted to verify the clinical efficacy of lysostaphin on sow endometritis. The average cure rate of 400u lysostaphin on sow endometritis(82.5%) was higher than the antibiotic group(72.17%). In addition, our results revealed that intravaginal administration of lysostaphin had no adverse effect on the reproductive performance of sows. Thus, this lysostaphin has potential application value as a new method alternative to antibiotics to treat endometritis in sows.

Indexed as

Administration, IntravaginalAnimalsAnti-Infective Agents, LocalChinaDose-Response Relationship, DrugEndometritisFemaleLysostaphinRandom AllocationRecombinant ProteinsSus scrofaTabletsTreatment OutcomeAnti-Infective Agents, LocalLysostaphinRecombinant ProteinsTabletsendometritisintravaginal administrationlysostaphinsow

Identifiers

PMID33389826
PMCPMC8136942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.